JP7330948B2 - トシル酸スプラタストを含む組成物 - Google Patents

トシル酸スプラタストを含む組成物 Download PDF

Info

Publication number
JP7330948B2
JP7330948B2 JP2020512637A JP2020512637A JP7330948B2 JP 7330948 B2 JP7330948 B2 JP 7330948B2 JP 2020512637 A JP2020512637 A JP 2020512637A JP 2020512637 A JP2020512637 A JP 2020512637A JP 7330948 B2 JP7330948 B2 JP 7330948B2
Authority
JP
Japan
Prior art keywords
film
tablet
release component
release
coated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020512637A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532548A5 (enExample
JP2020532548A (ja
Inventor
ボンド ハンセン，ジョン
ソンダーガード トムセン，ミカエル
ホジガード，ベント
Original Assignee
コンリグ ファーマ エーピーエス
ソルラル ファーマ エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンリグ ファーマ エーピーエス, ソルラル ファーマ エーピーエス filed Critical コンリグ ファーマ エーピーエス
Publication of JP2020532548A publication Critical patent/JP2020532548A/ja
Publication of JP2020532548A5 publication Critical patent/JP2020532548A5/ja
Application granted granted Critical
Publication of JP7330948B2 publication Critical patent/JP7330948B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020512637A 2017-08-29 2018-08-28 トシル酸スプラタストを含む組成物 Active JP7330948B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17188229.3 2017-08-29
EP17188229 2017-08-29
PCT/EP2018/073123 WO2019042995A1 (en) 2017-08-29 2018-08-28 COMPOSITION COMPRISING SUPLATAST TOSILATE

Publications (3)

Publication Number Publication Date
JP2020532548A JP2020532548A (ja) 2020-11-12
JP2020532548A5 JP2020532548A5 (enExample) 2021-09-30
JP7330948B2 true JP7330948B2 (ja) 2023-08-22

Family

ID=59745229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020512637A Active JP7330948B2 (ja) 2017-08-29 2018-08-28 トシル酸スプラタストを含む組成物

Country Status (8)

Country Link
US (1) US11819482B2 (enExample)
EP (1) EP3675831A1 (enExample)
JP (1) JP7330948B2 (enExample)
KR (1) KR20200045496A (enExample)
CN (1) CN111032021A (enExample)
AU (1) AU2018322756B2 (enExample)
CA (1) CA3073866A1 (enExample)
WO (1) WO2019042995A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507613A (ja) 1996-11-01 2000-06-20 アイレックス・オンコロジー・インコーポレイテッド Ｄｆｍｏ含有持続放出配合物
JP2001527034A (ja) 1997-12-23 2001-12-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング １種以上の活性物質を即時的ならびに持続的に放出するための錠剤
JP2002179554A (ja) 1997-09-05 2002-06-26 Takeda Chem Ind Ltd 医 薬
JP2002523358A (ja) 1998-08-25 2002-07-30 プラット，クリス ナプロキセンおよびプソイドエフェドリンを含む徐法性錠剤
WO2002087549A1 (fr) 2001-04-25 2002-11-07 Taisho Pharmaceutical Co., Ltd. Comprimes a liberation prolongee du type a unites multiples
JP2002541186A (ja) 1999-04-13 2002-12-03 ビーチャム・ファーマシューティカルズ・（プライベイト）・リミテッド 治療の新規方法
JP2002370968A (ja) 2001-06-12 2002-12-24 Towa Yakuhin Kk 薬物含有徐放性顆粒およびそれを含む錠剤
JP2005519053A (ja) 2002-01-09 2005-06-30 ユ セ ベ ソシエテ アノニム 放出が改良された薬剤
JP2006131521A (ja) 2004-11-04 2006-05-25 Taiho Yakuhin Kogyo Kk 頭痛の予防及び／または治療剤
JP2006335771A (ja) 2006-09-22 2006-12-14 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
JP2007535518A (ja) 2004-04-30 2007-12-06 トポターゲット ジャーマニィ アーゲー ヒストンデアセチラーゼ阻害剤を含んで成る製剤
JP2010510241A (ja) 2006-11-17 2010-04-02 スパーナス ファーマシューティカルズ インコーポレイテッド トピラマートの徐放性配合物
JP2011246454A (ja) 2010-04-27 2011-12-08 Daiichi Sankyo Healthcare Co Ltd 安全な免疫抑制剤または免疫異常抑制剤組成物
WO2017032384A1 (en) 2015-08-25 2017-03-02 Conrig Pharma Aps Compound and use in the treatment of cough

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556737A (en) 1983-03-11 1985-12-03 Taiho Pharmaceutical Company Limited Sulfonium compounds, processes for preparing the compounds and pharmacological composiitons containing the same
JPS6168455A (ja) 1984-09-12 1986-04-08 Taiho Yakuhin Kogyo Kk アミド化合物
JPH0370698A (ja) 1989-08-11 1991-03-26 Naomasa Nomura 頭部回転式高性能飛行機
WO1995003052A1 (en) 1993-07-22 1995-02-02 Warner-Lambert Company Controlled release tacrine drug delivery systems and methods for preparing same
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7138140B2 (en) * 2001-04-16 2006-11-21 Taiho Pharmaceutical Co., Ltd. Suplatast tosilate crystals
US20100092562A1 (en) 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
WO2007001058A1 (ja) * 2005-06-27 2007-01-04 Juntendo Educational Foundation ヘルペスウイルス由来疼痛治療剤
WO2008119988A1 (en) * 2007-03-30 2008-10-09 Cardoz Ab New combination for use in the treatment of inflammatory disorders
CN101028254B (zh) * 2007-04-05 2010-05-19 合肥合源医药科技股份有限公司 一种多索茶碱缓释制剂及其制备方法
CN101590022A (zh) * 2008-05-29 2009-12-02 焦作平光制药有限责任公司 甘氨酸茶碱钠缓释片及其制备方法
CN102210688B (zh) 2011-05-24 2013-04-03 赛乐医药科技(上海)有限公司 复方甲氧那明的速释-缓释制剂
WO2016192680A1 (en) * 2015-06-03 2016-12-08 Triastek, Inc. Dosage forms and use thereof
DK3393463T3 (da) * 2015-12-23 2021-04-26 Conrig Pharma Aps Suplatast-tosilat til behandling af hoste forbundet med interstitiel lungesygdom

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507613A (ja) 1996-11-01 2000-06-20 アイレックス・オンコロジー・インコーポレイテッド Ｄｆｍｏ含有持続放出配合物
JP2002179554A (ja) 1997-09-05 2002-06-26 Takeda Chem Ind Ltd 医 薬
JP2001527034A (ja) 1997-12-23 2001-12-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング １種以上の活性物質を即時的ならびに持続的に放出するための錠剤
JP2002523358A (ja) 1998-08-25 2002-07-30 プラット，クリス ナプロキセンおよびプソイドエフェドリンを含む徐法性錠剤
JP2002541186A (ja) 1999-04-13 2002-12-03 ビーチャム・ファーマシューティカルズ・（プライベイト）・リミテッド 治療の新規方法
WO2002087549A1 (fr) 2001-04-25 2002-11-07 Taisho Pharmaceutical Co., Ltd. Comprimes a liberation prolongee du type a unites multiples
JP2002370968A (ja) 2001-06-12 2002-12-24 Towa Yakuhin Kk 薬物含有徐放性顆粒およびそれを含む錠剤
JP2005519053A (ja) 2002-01-09 2005-06-30 ユ セ ベ ソシエテ アノニム 放出が改良された薬剤
JP2007535518A (ja) 2004-04-30 2007-12-06 トポターゲット ジャーマニィ アーゲー ヒストンデアセチラーゼ阻害剤を含んで成る製剤
JP2006131521A (ja) 2004-11-04 2006-05-25 Taiho Yakuhin Kogyo Kk 頭痛の予防及び／または治療剤
JP2006335771A (ja) 2006-09-22 2006-12-14 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
JP2010510241A (ja) 2006-11-17 2010-04-02 スパーナス ファーマシューティカルズ インコーポレイテッド トピラマートの徐放性配合物
JP2011246454A (ja) 2010-04-27 2011-12-08 Daiichi Sankyo Healthcare Co Ltd 安全な免疫抑制剤または免疫異常抑制剤組成物
WO2017032384A1 (en) 2015-08-25 2017-03-02 Conrig Pharma Aps Compound and use in the treatment of cough

Also Published As

Publication number Publication date
EP3675831A1 (en) 2020-07-08
WO2019042995A1 (en) 2019-03-07
AU2018322756A1 (en) 2020-03-19
JP2020532548A (ja) 2020-11-12
CA3073866A1 (en) 2019-03-07
CN111032021A (zh) 2020-04-17
US20200230083A1 (en) 2020-07-23
KR20200045496A (ko) 2020-05-04
US11819482B2 (en) 2023-11-21
AU2018322756B2 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
US10441585B2 (en) Formulations containing nalbuphine and uses thereof
EP1878444B1 (en) Composition containing anti-dementia drug
JP6976946B2 (ja) 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物
US20170119663A1 (en) Novel gastro-retentive dosage forms
BR112012028035A2 (pt) forma de dosagem e formulação de liberação imediata, e, uso das mesmas
CN105658207A (zh) 用于以低的日剂量施用的含富马酸二甲酯的药物组合物
ES2529455T3 (es) Sistema de administración de fármacos por dosis controladas
US7192608B2 (en) Method of manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules
WO2013139209A1 (zh) 托吡酯缓释药物组合物、其制备方法及用途
EA039091B1 (ru) Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин
JP4438268B2 (ja) 薬物顆粒の製造方法、および薬物顆粒、ならびにそれを用いた医薬製剤
JP7330948B2 (ja) トシル酸スプラタストを含む組成物
CN101756981B (zh) 一种布洛氯雷伪麻缓释制剂及其制备方法
CN108066304B (zh) 具有缓释性能的坦索罗辛口腔崩解片组合物
EP3796908A1 (en) Controlled release propiverine formulations
WO2011027322A1 (en) Extended release dosage form containing olopatadine for oral administration
CN102232934B (zh) 一种脉冲微丸及含其的脉冲口腔崩解片,制备方法和用途
KR20040005257A (ko) 방출제어형 약제학적 조성물
US20210346303A1 (en) Coating method
US20150238615A1 (en) Denaturants for sympathomimetic amines
US20090162431A1 (en) Sustained release formulations containing acetaminophen and tramadol
CN108066347A (zh) 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物
KR20180002437A (ko) 독실아민 및 피리독신을 포함하는 약제학적 복합 제제
WO2010123440A1 (en) Pharmaceutical composition comprising 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n- propylcinnoline-3-carboxamide hydrogen sulphate and rate-controlling polymer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210818

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230809

R150 Certificate of patent or registration of utility model

Ref document number: 7330948

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150